<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>The main market opportunities for PD-L1 x 4-1BB bispecific antibodies lie in their ability to target tumors precisely while minimizing liver toxicity, addressing a gap in cancer therapy. These therapies exploit tumor-enriched environments for enhanced T-cell and NK cell activation, promising next-gen anticancer efficacy.Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/6179395/pipeline-pd-l1-x-4-1bb-cd137-bispecific?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=9tlqqt&amp;utm_campaign=2252532+-+PD-L1+X+4-1BB+(CD137)+Bispecific+Antibodies+Pipeline+Competitor+Analysis+Report+2026%3a+Active+R%26D+Programs+by+R%26D+Phase+and+Profile+of+Bispecific+Antibodies+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="Pipeline of PD-L1 x 4-1BB (CD137) Bispecific Antibodies">"Pipeline of PD-L1 x 4-1BB (CD137) Bispecific Antibodies"</a> report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about PD-L1 x 4-1BB (CD137) Bispecific Antibodies provides an up-to-date competitor evaluation in the field of emerging therapy candidates in research and development targeting simultaneously PD-L1 and 4-1BB (CD137). This report will be prepared on demand within one working day upon order placement. The report lists active PD-L1 x 4-1BB targeted R&amp;D programs by R&amp;D phase in a tabular format and describes in brief the profile of PD-L1 x 4-1BB bispecific antibodies by drug modality. 4-1BB (CD137, TNFRSF9) is a costimulatory receptor of the TNF receptor superfamily (TNFRSF) and accumulates on the T-cell surface upon activation. Receptor stimulation by endogenous 4-1BB ligand (4-1BBL) or agonistic 4-1BB antibodies can markedly augment T-cell activation and upregulate inflammatory cytokine response. Agonistic 4-1BB antibodies have exhibited potent anticancer efficacy in a variety of syngeneic mouse models. However, the on-target-off-tumor liver toxicity has hampered the successful clinical development of therapeutic 4-1BB agonists. Programmed death-ligand 1 (PD-L1) also known as CD274 or B7 homolog 1 (B7-H1) is a a 40kDa type 1 transmembrane protein playing a major role in suppressing the adaptive arm of immune systems during particular events. The binding of PD-L1 to the inhibitory checkpoint molecule PD-1 transmits an inhibitory signal which reduces the proliferation of antigen-specific T-cells in lymph nodes, while simultaneously reducing apoptosis in regulatory T cells. PD-L1 is expressed on both hematopoietic and nonhematopoietic cells in tissues. PD-L1 is shown to be highly expressed in a variety of malignancies, particularly lung cancer. One of the most promising next-generation 4-1BB targeting strategies is the use of bispecific antibodies (BsAb) or bispecific fusion proteins, which are designed to be enriched in the tumor microenvironment (TME) enabling tumor cell-mediated 4-1BB activation, thereby minimizing on-target-off-tumor toxicity. Typically, such bispecific proteins are composed of a tumor-associated antigen (TAA)-recognizing arm and a 4-1BB-agonistic arm. A number of PD-L1 x 4-1BB bispecific antibodies are in preclinical and clinical development which were designed to elicit an antitumor response via conditional activation of 4-1BB on T cells and natural killer (NK) cells, which is strictly dependent on simultaneous binding of the PD-L1 arm. For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6179395/pipeline-pd-l1-x-4-1bb-cd137-bispecific?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=9tlqqt&amp;utm_campaign=2252532+-+PD-L1+X+4-1BB+(CD137)+Bispecific+Antibodies+Pipeline+Competitor+Analysis+Report+2026%3a+Active+R%26D+Programs+by+R%26D+Phase+and+Profile+of+Bispecific+Antibodies+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/2cw0g5</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MTAyZTA4ZmYtYWQ5My00YzBhLWE0OTItM2JiYmRhMmFlMjJiLTEwMjY3MzctMjAyNi0wNS0xNC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

PD-L1 X 4-1BB (CD137) Bispecific Antibodies Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Bispecific Antibodies by Drug Modality

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn